SARS News and Research

RSS

Study links long COVID to gut inflammation and serotonin deficiency

Patients with long COVID – the long-term symptoms like brain fog, fatigue, or memory loss in the months or years following COVID-19 – can exhibit a reduction in circulating levels of the neurotransmitter serotonin, according to new research published today in Cell.

16 Oct 2023

New mRNA flu vaccine shows promise: Faster to produce, highly effective in mice

The study evaluates the efficacy of a new quadrivalent mRNA influenza vaccine, finding it to be highly immunogenic and protective in a mouse model. Compared to traditional vaccines, the mRNA-based option offers advantages like reduced production time and elimination of the risk of growth-promoting mutations.

15 Oct 2023

Is it time to rethink COVID-19 boosters? New study dives into variant-specific vaccines

The study explores the efficacy of variant-adapted COVID-19 booster vaccines, particularly against new strains like Omicron. It raises questions about the need for annual updates and the best technologies for long-term, durable immunity.

15 Oct 2023

Early and severe: Kids hit hard by 2022-23 flu season, vaccination rates drop

The 2022-23 influenza season saw a highly severe impact on U.S. adolescents and children, with early peaks in hospitalization rates and outpatient visits. The study underscores the importance of flu vaccination and antiviral treatment, especially as fewer hospitalized children were vaccinated compared to previous seasons.

15 Oct 2023

Are people with HIV at a higher risk of severe COVID-19 outcomes?

The research review indicates that people with HIV, especially those with low CD4 cell counts, face greater risks of severe COVID-19 outcomes and have suboptimal immune responses to SARS-CoV-2. Antiretroviral therapy aids in clearing infections, and a third vaccine dose reduces the risk of breakthrough infections among this population.

15 Oct 2023

Cerba Research expands expertise and global reach to support drug development

Cerba Research is transforming into a multi-specialist and central laboratory company, providing research organisations with even greater access to exceptional scientific and technical teams in multiple therapeutic areas for drug and vaccine development.

14 Oct 2023

New insights into coronavirus E channel could lead to antiviral drugs

The genome of the SARS-CoV-2 virus encodes 29 proteins, one of which is an ion channel called E. This channel, which transports protons and calcium ions, induces infected cells to launch an inflammatory response that damages tissues and contributes to the symptoms of Covid-19.

13 Oct 2023

Strong antibody response and nasal cytokines may protect young children from severe COVID-19

New research helps explain why young children have lower rates of severe COVID-19 than adults. A study of infants and young children found those who acquired SARS-CoV-2 had a strong, sustained antibody response to the virus and high levels of inflammatory proteins in the nose but not in the blood.

13 Oct 2023

Moderna's updated COVID-19 vaccine for Autumn 2023 outperforms in cost and clinical impact

Moderna's updated mRNA-1273.815 COVID-19 vaccine shows promising results in reducing symptomatic cases, hospitalizations, and deaths in high-risk and older adults in Germany. The study finds the vaccine to be more cost-effective and clinically beneficial than both no vaccination and Pfizer's XBB.1.5 BNT162b2 vaccine.

12 Oct 2023

EVScape: New tool to forecast which SARS-CoV-2 variants could dodge our immunity

Researchers have developed EVScape, a predictive tool that identifies which SARS-CoV-2 strains are most likely to evade host immunity. Utilizing a deep generative model and structural information, the tool offers early warning about viral variants, aiding in the timely development of effective vaccines and treatments.

12 Oct 2023

Healthcare settings and mpox transmission: Understanding the risk factors

The stability of the monkeypox (Mpox) virus in various surroundings and bodily fluid.

12 Oct 2023

OrganaBio launches new division to meet growing demand for decentralized clinical trial support

OrganaBio, the Contract Technology Development and Manufacturing Organization (CTDMO) specializing in solutions for cell and immunotherapy development, today announces the official launch of Cell Processing and Cryopreservation (CPC) Services, a new division of OrganaBio.

12 Oct 2023

New AI tool predicts future viral variants using evolutionary, biological information

The COVID-19 pandemic seemed like a never-ending parade of SARS-CoV-2 variants, each equipped with new ways to evade the immune system, leaving the world bracing for what would come next.

11 Oct 2023

Adaptability and promising potential of synthetic information in healthcare

The possible benefits and limits of artificially generated data in the context of healthcare analytics.

11 Oct 2023

Inflammatory diseases don't boost clotting risks post-COVID, study reveals

Canadian researchers found that patients with immune-mediated inflammatory diseases (IMIDs) don't face a heightened risk of venous thromboembolism events after recovering from COVID-19 compared to those without IMIDs. However, certain comorbidities can influence this risk, emphasizing the importance of individualized patient care.

11 Oct 2023

SARS News and Research

Study links long COVID to gut inflammation and serotonin deficiency

New mRNA flu vaccine shows promise: Faster to produce, highly effective in mice

Is it time to rethink COVID-19 boosters? New study dives into variant-specific vaccines

Early and severe: Kids hit hard by 2022-23 flu season, vaccination rates drop

Are people with HIV at a higher risk of severe COVID-19 outcomes?

Cerba Research expands expertise and global reach to support drug development

New insights into coronavirus E channel could lead to antiviral drugs

Strong antibody response and nasal cytokines may protect young children from severe COVID-19

Moderna's updated COVID-19 vaccine for Autumn 2023 outperforms in cost and clinical impact

EVScape: New tool to forecast which SARS-CoV-2 variants could dodge our immunity

Healthcare settings and mpox transmission: Understanding the risk factors

OrganaBio launches new division to meet growing demand for decentralized clinical trial support

New AI tool predicts future viral variants using evolutionary, biological information

Adaptability and promising potential of synthetic information in healthcare

Inflammatory diseases don't boost clotting risks post-COVID, study reveals

COVID-19 vaccine response lower in patients with lung conditions, study finds

SARS-CoV-2 RNA found in ocular tissues at autopsy, despite minimal inflammation

Did the COVID-19 pandemic increase drunkness among people with a history of alcohol use disorder?

Comparing the lasting effects: post COVID vs. non-COVID acute respiratory infections

COVID-19 heightens risk of autoimmune disorders

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News